News - Anti-Arthritics/Rheumatics, Fosamax


Popular Filters

DMC clears Merck & Co’s Alzheimer’s drug MK-8931 development

DMC clears Merck & Co’s Alzheimer’s drug MK-8931 development


The development program for MK-8931, a novel investigational oral beta-amyloid precursor protein site-cleaving…

Anti-Arthritics/RheumaticsFinancialFosamaxMerck & CoMK-8931NeurologicalNorth AmericaPharmaceuticalResearch

Merck & Co wins Fosamax federal bellwether trial over atypical femur fracture claims


A US has jury found in favor of pharma giant Merck & Co (NYSE: MRK) in the Glynn versus Merck case in…

Anti-Arthritics/RheumaticsFosamaxLegalMerck & CoNorth AmericaPharmaceutical

Another Fosamax trial success for Merck & Co


US drugs giant Merck & Co (NYSE: MRK) says that a federal court jury in New York found in its favor in…

Anti-Arthritics/RheumaticsFosamaxLegalMerck & CoNorth AmericaPharmaceutical

Two US FDA advisory panels say osteoporosis drugs need label changes


Experts advising the US Food and Drug Administration have recommended revised labeling for bisphosphonates,…

ActonelAnti-Arthritics/RheumaticsBonvivaFosamaxMerck & CoNorth AmericaPharmaceuticalReclastRegulationRocheWarner Chilcott

Canadian Superior Court refuses authorization for class action against Merck & Co


Canada’s Quebec Superior Court recently dismissed a motion filed by Option consommateurs for authorization…

Anti-Arthritics/RheumaticsFosamaxLegalMerck & CoPharmaceutical

Back to top